Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practices
October 06 2020 - 8:15AM
Business Wire
- Clinical findings to be presented on PRECISION1® daily
disposable contact lenses and Systane® family of dry eye
products
- Meeting attendees will have opportunity to get an exclusive
demo of MARLO, Alcon’s new digital platform
- Interactive virtual Alcon booth will offer clinical education
learning lab, product innovations, an OD-to-OD live theater, a
COVID-19 practice response section and more
Alcon, the global leader in eye care, will highlight leading
innovations and clinical research at the 2020 American Academy of
Optometry (the Academy or #Academy20) meeting taking place
virtually from October 7 – 22, 2020. The company’s robust virtual
program will feature updates on its most important innovations,
including PRECISION1® one-day contact lenses, Systane® iLux® MGD
Treatment System and digital platform MARLO, as well as 23
scientific presentations on a range of technologies.
“Now more than ever, there’s an increasing need to bolster
practice growth and deliver on unmet patient needs during these
challenging times,” said Sean Clark, VP/General Manager, U.S.
Vision Care, Alcon. “Throughout the COVID-19 pandemic, Alcon has
doubled down on our commitment to support Eye Care Professionals by
providing tools, resources and programs to support their practices
and their patients. We believe the innovations we’re bringing to
this year’s Academy meeting will help our partners get back to
business so we can continue helping people See Brilliantly
together.”
Alcon’s virtual booth will feature a live theater offering
OD-to-OD education and Q&A sessions; an in-depth learning lab;
resources for Eye Care Professionals (ECPs) to help their practices
recover following COVID-19 shutdowns; product innovation showcases;
direct support from Alcon’s medical affairs team; a fun,
interactive game center to get the full event experience at home;
and, more.
Clinical Data Highlights Key Benefits of PRECISION1 Contact
Lenses
Clinical findings will be presented at #Academy20, highlighting
key attributes of Alcon’s latest contact lens innovation,
PRECISION1. Specifically, data presented at the meeting will look
at the lens’ overall performance, efficacy during digital device
use and the clinical performance of a forthcoming toric version of
PRECISION1. PRECISION1 meeting highlights include:
- Friday, October 9
- Paper Presentation: Clinical Comparison of Verofilcon A and
Etafilcon A Daily Disposable Contact Lenses. Presented by Dr. Jason
Miller, 3:15 – 3:30 p.m. ET
- Poster Presentation: The subjective response to Verofilcon A
Daily Disposable Contact Lenses During Extensive Digital Device
Use. Presented by Dr. Marc Schulze, 4:00 – 6:00 p.m. ET
- Poster Presentation: Clinical Performance of Verofilcon A Toric
Daily Disposable Silicone Hydrogel Contact Lenses. Presented by Dr.
Wilson Movic, 4:00 – 6:00 p.m. ET
- Poster Presentation: Use of Likert Questionnaires to Compare
Subjective Performance of Two Daily Disposable Soft Contact Lenses.
Presented by Dr. Jason Miller, 4:00 – 6:00 p.m. ET
- Friday, October 16
- Lunch Symposium: The Next Big Thing, featuring PRECISION1.
Guest Speaker Dr. Pam Lowe, 12:00 – 1:00 p.m. ET
Broadened U.S. Availability of MARLO Helps ODs Stay Connected
to their Patients
Following a successful pilot, Alcon announced in August the
broader U.S. availability of its innovative MARLO digital platform.
This platform is the contact lens ordering experience patients
expect from online retailers and, now, independent OD practices can
offer it to their patients. Alcon accelerated MARLO access to help
ECPs better connect with their patients as virtual health services
became more popular due to COVID-19. Meeting-goers will be able to
visit the MARLO section of Alcon’s virtual booth to sign up for a
demo of the product. For more information, visit MeetMarlo.com.
Clinical Research and Opportunities in Dry Eye
Alcon’s dry eye portfolio of drops and devices will be featured
in scientific presentations during the virtual #Academy20 meeting,
including:
- Wednesday, October 7
- Poster Presentation: iLux Efficacy after One Week of Treatment.
Presented by Dr. David Geffen, 4:00 – 6:00 p.m. ET
- Poster Presentation: Dry Eye Symptom Relief with a
Phospholipid/Propylene Glycol/Hydroxypropyl Guar Nanoemulsion
ocular lubricant. Presented by Dr. Thao Yeh, 4:00 – 6:00 p.m.
ET
- Poster Presentation: Six-Month Therapeutic Profiles of Lipid
and Non-Lipid-Based Artificial Tear Supplements in Managing Dry Eye
Disease. Presented by Dr. Jennifer Craig, 4:00 – 6:00 p.m. ET
Visit the Alcon virtual booth in the exhibits section of
www.AcademyMeeting.org for important information on Alcon’s
innovative products and programs featured in this release.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201006005458/en/
Alcon Media Relations
Kimberly Wise +1 817 615 5092 (direct) +1 817 525 3409 (mobile)
kimberly.wise@alcon.com Alcon Investor
Relations Christina Cheng +41 589 112 110 (Geneva) +1
817 615 2789 (Fort Worth) investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Apr 2023 to Apr 2024